Shares of Amgen Inc. AMGN slipped 1.01% to $258.59 Monday, on what proved to be an all-around mixed trading session for the ...

CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.

Amgen (AMGN) closed at $258.59 in the latest trading session, marking a -1.01% move from the prior day. This move lagged the S&P 500's daily gain of 0.55%. At the same time, the Dow lost 0.06%, and ...

Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...

Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.38 on 7th ...

Bearish flow noted in Amgen (AMGN) with 6,559 puts trading, or 1.0x expected. Most active are Feb-25 240 puts and 1/10 weekly 260 calls, with ...

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Exxon Mobil ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

Amgen's Imdylltra gets MHRA nod for ES-SCLC after two prior therapies, offering new hope for aggressive cancer with limited ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...